magrolimab + docetaxel

**Magrolimab + docetaxel** is an investigational combination therapy being studied for patients with advanced solid tumors, including metastatic non-small cell lung cancer (mNSCLC), metastatic urothelial cancer (mUC), metastatic small cell lung cancer (mSCLC), and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC). **Magrolimab** is a monoclonal antibody that targets and blocks CD47, a cell surface “don’t eat me” signal on tumor cells, enhancing macrophage-mediated phagocytosis of cancer cells. **Docetaxel** is a small molecule chemotherapy agent (a taxane) that promotes microtubule assembly and inhibits microtubule disassembly, leading to cell cycle arrest and apoptosis. Preclinical evidence suggests taxanes like docetaxel can increase prophagocytic signals on tumor cells, creating a potentially synergistic antitumor effect with magrolimab. The combination is being evaluated in ongoing phase 2 clinical trials for safety, tolerability, and efficacy[1][2][3].